Radiotherapy for pediatric adrenocortical carcinoma - Review of the literature.
Pediatric adrenocortical cancer
Pediatric adrenocortical carcinoma
Pediatric adrenocortical tumor
Radiotherapy
Therapy
Treatment
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
22
03
2022
revised:
12
05
2022
accepted:
12
05
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
Pediatric adrenocortical carcinoma (pACC) is a rare disease with poor prognosis. Publications on radiotherapy (RT) are scarce. This review summarizes the current data on RT for pACC and possibly provides first evidence to justify its use in this setting. We searched the PubMed and Embase database for manuscripts regarding RT for pACC. We included 17 manuscripts reporting on 76 patients treated with RT, after screening 2961 references and 269 full articles. In addition, we added data of 4 unreported pACC patients treated by co-authors. All reports based on retrospective data. Median age at first diagnosis was 11.1 years (70% female); 78% of patients presented with hormonal activity. RT was mostly performed for curative intent (78%). 88% of RT were administered during primary therapy. The site of RT was predominantly the local tumor bed (76%). Doses of RT ranged from 15 to 62 Gy (median 50 Gy). Information on target volumes or fractionation were lacking. Median follow-up was 6,9 years and 64% of the patients died of disease, with 33% alive without disease. In 16 of 48 patients with available follow-up data after adjuvant RT (33%) no recurrence was reported and in 3 of 9 patients palliative RT seemed to induce some benefit for the patient. Our first systematic review on RT for pACC provides too few data for any general recommendation, but adjuvant RT in patients with high risk might be considered. International collaborative studies are urgently needed to establish better evidence on the role of RT in this rare malignancy.
Sections du résumé
Background and purpose
UNASSIGNED
Pediatric adrenocortical carcinoma (pACC) is a rare disease with poor prognosis. Publications on radiotherapy (RT) are scarce. This review summarizes the current data on RT for pACC and possibly provides first evidence to justify its use in this setting.
Materials and methods
UNASSIGNED
We searched the PubMed and Embase database for manuscripts regarding RT for pACC.
Results
UNASSIGNED
We included 17 manuscripts reporting on 76 patients treated with RT, after screening 2961 references and 269 full articles. In addition, we added data of 4 unreported pACC patients treated by co-authors. All reports based on retrospective data. Median age at first diagnosis was 11.1 years (70% female); 78% of patients presented with hormonal activity. RT was mostly performed for curative intent (78%). 88% of RT were administered during primary therapy. The site of RT was predominantly the local tumor bed (76%). Doses of RT ranged from 15 to 62 Gy (median 50 Gy). Information on target volumes or fractionation were lacking. Median follow-up was 6,9 years and 64% of the patients died of disease, with 33% alive without disease. In 16 of 48 patients with available follow-up data after adjuvant RT (33%) no recurrence was reported and in 3 of 9 patients palliative RT seemed to induce some benefit for the patient.
Conclusions
UNASSIGNED
Our first systematic review on RT for pACC provides too few data for any general recommendation, but adjuvant RT in patients with high risk might be considered. International collaborative studies are urgently needed to establish better evidence on the role of RT in this rare malignancy.
Identifiants
pubmed: 35601796
doi: 10.1016/j.ctro.2022.05.003
pii: S2405-6308(22)00040-4
pmc: PMC9121070
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
56-63Informations de copyright
© 2022 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
N Engl J Med. 1990 Apr 26;322(17):1195-201
pubmed: 2325710
Eur J Hum Genet. 2020 Oct;28(10):1379-1386
pubmed: 32457520
Mod Pathol. 2019 Apr;32(4):546-559
pubmed: 30401946
Exp Clin Endocrinol Diabetes. 2019 Feb;127(2-03):109-116
pubmed: 30469158
Front Endocrinol (Lausanne). 2015 Feb 18;6:23
pubmed: 25741319
Pediatr Hematol Oncol. 1998 Nov-Dec;15(6):527-32
pubmed: 9842646
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5
pubmed: 11481490
N Engl J Med. 2002 Apr 11;346(15):1128-37
pubmed: 11948273
J Clin Endocrinol Metab. 2006 Nov;91(11):4501-4
pubmed: 16895957
Cancer. 2009 Jul 1;115(13):2816-23
pubmed: 19402169
Pediatr Blood Cancer. 2020 Feb;67(2):e28086
pubmed: 31738008
Eur J Endocrinol. 2021 Feb;184(2):R51-R59
pubmed: 33166271
Cancer. 2016 Dec 1;122(23):3673-3681
pubmed: 27496084
Front Oncol. 2021 Sep 30;11:751784
pubmed: 34660315
Nat Rev Endocrinol. 2011 Jun;7(6):323-35
pubmed: 21386792
Front Oncol. 2021 Jan 20;10:617506
pubmed: 33552991
J Urol. 2005 Dec;174(6):2338-42, discussion 2342
pubmed: 16280838
J Clin Endocrinol Metab. 2013 Jan;98(1):181-91
pubmed: 23150691
Endocrine. 2021 Dec;74(3):475-477
pubmed: 34559356
Gastric Cancer. 2021 Jul;24(4):959-969
pubmed: 33576929
Cancers (Basel). 2021 Oct 20;13(21):
pubmed: 34771430
Eur Urol Focus. 2016 Feb;1(3):241-250
pubmed: 28723392
Endocr Pathol. 1992 Sep;3(3):116-128
pubmed: 32138394
J Clin Endocrinol Metab. 2019 Sep 1;104(9):3743-3750
pubmed: 31220287
J Pediatr Surg. 2011 Jun;46(6):1201-7
pubmed: 21683223
J Pediatr Surg. 2008 May;43(5):843-9
pubmed: 18485950
J Pediatr Urol. 2021 Oct;17(5):735.e1-735.e6
pubmed: 34210620
Cancer Med. 2020 Nov;9(21):7954-7963
pubmed: 32931654
Pediatr Blood Cancer. 2017 Jun;64(6):
pubmed: 27957799
Cancer. 2009 Jan 15;115(2):243-50
pubmed: 19025987
Arq Bras Endocrinol Metabol. 2004 Oct;48(5):647-50
pubmed: 15761534
Pediatr Blood Cancer. 2021 Jun;68 Suppl 4:e29025
pubmed: 34174161
Pediatr Dev Pathol. 2009 Jul-Aug;12(4):284-91
pubmed: 19326954
J Clin Oncol. 2015 Jul 20;33(21):2345-52
pubmed: 26014290
Urol Oncol. 2021 Nov;39(11):791.e1-791.e7
pubmed: 34301459
J Clin Oncol. 2004 Mar 1;22(5):838-45
pubmed: 14990639
BJS Open. 2019 May 03;3(5):672-677
pubmed: 31592096
J Pediatr Surg. 2013 May;48(5):1025-31
pubmed: 23701777
Surg Oncol Clin N Am. 2021 Apr;30(2):275-290
pubmed: 33706900
Horm Res Paediatr. 2018;90(1):8-18
pubmed: 29804118
Radiat Oncol. 2020 May 24;15(1):118
pubmed: 32448148
Ann Surg Oncol. 2019 Feb;26(2):531-538
pubmed: 30443830
Lancet Oncol. 2021 Dec;22(12):e562-e574
pubmed: 34856153
Klin Padiatr. 1986 May-Jun;198(3):250-6
pubmed: 3723989
J Cancer Res Ther. 2019 Mar;15(Supplement):S20-S26
pubmed: 30900615
Am J Surg Pathol. 2003 Jul;27(7):867-81
pubmed: 12826878
Eur J Endocrinol. 2018 Oct 01;179(4):G1-G46
pubmed: 30299884
J Clin Oncol. 2021 Aug 1;39(22):2463-2473
pubmed: 33822640
Ann Surg. 2012 Feb;255(2):363-9
pubmed: 22143204
BJU Int. 2002 Apr;89(6):562-5
pubmed: 11942965
Ann Oncol. 2020 Nov;31(11):1476-1490
pubmed: 32861807
J Clin Oncol. 2015 Feb 20;33(6):602-9
pubmed: 25584008
J Clin Endocrinol Metab. 2013 Dec;98(12):4551-64
pubmed: 24081734
Int J Surg. 2021 Feb;86:24-31
pubmed: 33429078
Cancer. 1996 Feb 15;77(4):771-7
pubmed: 8616771
Klin Padiatr. 2012 Oct;224(6):366-71
pubmed: 23143764
J Pediatr Surg. 2014 Sep;49(9):1367-71
pubmed: 25148739